Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Abstract

OBJECTIVE:

To investigate the relationship between the Bcl-2 and survivin expression and the different regimens therapeutic efficacy newly diagnosed multiple myeloma (NDMM).

METHODS:

We retrospectively assessed the association of Bcl-2 and survivin expression with chemotherapeutic efficacy and prognosis in 59 NDMM patients in a single center.

RESULTS:

The positive expression rate for survivin and Bcl-2 was 35% and 74%, respectively. Survivin and Bcl-2 protein expression were not associated with clinical stage, suggesting that they are not related to tumor burden in NDMM. Bortezomib-based regimens were more effective in reducing tumor burden and achieving therapeutic (complete and partial) response compared with non-bortezomib-based regimens irrespective of Bcl-2 or survivin expression (P < 0.05). In cases with both negative Bcl-2 and survivin expression (Bcl-2(-)survivin(-)), the response to bortezomib and non-bortezomib-based regimens was similar (p = 0.429). Bcl-2 and survivin expression were not correlated with overall survival (OS); however, Bcl-2-survivin- cases showed a trend towards a longer OS (P = 0.078).

CONCLUSION:

We recommend bortezomib-containing regimens for NDMM with single or double-positive Bcl-2 and survivin expression.

• Authors: Wen Zeng, Fankai Meng, Zeming Liu, Xia Mao, Li Luo, Miao Zheng, Shuang Qin, Wenli Liu, Jianfeng Zhou, Hanying Sun, Lifang Huang
• Journal: International journal of clinical and experimental pathology (Int J Clin Exp Pathol) Vol. 7 Issue 7 Pg. 4239-46 ( 2014) ISSN: 1936-2625 [Electronic] United States
• PMID: 25120804 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• BIRC5 protein, human
• Boronic Acids
• Inhibitor of Apoptosis Proteins
• Proto-Oncogene Proteins c-bcl-2
• Pyrazines
• Survivin
• Thalidomide
• Vincristine
• Bortezomib
• Dexamethasone
• Doxorubicin
• Melphalan
• Prednisone

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Boronic Acids (therapeutic use)
• Bortezomib
• Dexamethasone (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Immunohistochemistry
• Inhibitor of Apoptosis Proteins (biosynthesis)
• Kaplan-Meier Estimate
• Male
• Melphalan (administration & dosage)
• Middle Aged
• Multiple Myeloma (drug therapy, metabolism, mortality)
• Prednisone (administration & dosage)
• Prognosis
• Proto-Oncogene Proteins c-bcl-2 (biosynthesis)
• Pyrazines (therapeutic use)
• Retrospective Studies
• Survivin
• Thalidomide (administration & dosage)
• Vincristine (administration & dosage)